1. Home
  2. PHAR vs THRY Comparison

PHAR vs THRY Comparison

Compare PHAR & THRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$17.87

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Thryv Holdings Inc.

THRY

Thryv Holdings Inc.

HOLD

Current Price

$5.82

Market Cap

257.5M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHAR
THRY
Founded
1988
2012
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
257.5M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PHAR
THRY
Price
$17.87
$5.82
Analyst Decision
Strong Buy
Buy
Analyst Count
3
4
Target Price
$30.00
$14.00
AVG Volume (30 Days)
20.3K
983.0K
Earning Date
11-06-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.00
0.40
Revenue
$362,274,000.00
$779,992,000.00
Revenue This Year
$24.80
N/A
Revenue Next Year
$6.84
N/A
P/E Ratio
$3,084.39
$14.46
Revenue Growth
26.78
N/A
52 Week Low
$7.50
$5.25
52 Week High
$18.12
$20.92

Technical Indicators

Market Signals
Indicator
PHAR
THRY
Relative Strength Index (RSI) 60.83 36.88
Support Level $15.76 $5.63
Resistance Level $17.35 $6.26
Average True Range (ATR) 0.77 0.29
MACD 0.02 0.22
Stochastic Oscillator 89.41 53.51

Price Performance

Historical Comparison
PHAR
THRY

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About THRY Thryv Holdings Inc.

Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. Its company is built upon a rich legacy in the marketing and advertising industry. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable SMB clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation, and run their day-to-day operations to save time, compete and win in today's SMB environment. The group has two business segments; Thryv SaaS and Thryv Marketing Services.

Share on Social Networks: